Browse MAPK7

Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Nucleus, PML body. Note=Translocates to the nucleus upon activation.
Domain PF00069 Protein kinase domain
Function

Plays a role in various cellular processes such as proliferation, differentiation and cell survival. The upstream activator of MAPK7 is the MAPK kinase MAP2K5. Upon activation, it translocates to the nucleus and phosphorylates various downstream targets including MEF2C. EGF activates MAPK7 through a Ras-independent and MAP2K5-dependent pathway. May have a role in muscle cell differentiation. May be important for endothelial function and maintenance of blood vessel integrity. MAP2K5 and MAPK7 interact specifically with one another and not with MEK1/ERK1 or MEK2/ERK2 pathways. Phosphorylates SGK1 at Ser-78 and this is required for growth factor-induced cell cycle progression. Involved in the regulation of p53/TP53 by disrupting the PML-MDM2 interaction.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001525 angiogenesis
GO:0001933 negative regulation of protein phosphorylation
GO:0006140 regulation of nucleotide metabolic process
GO:0006195 purine nucleotide catabolic process
GO:0006198 cAMP catabolic process
GO:0006469 negative regulation of protein kinase activity
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0006979 response to oxidative stress
GO:0007162 negative regulation of cell adhesion
GO:0007369 gastrulation
GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress
GO:0009150 purine ribonucleotide metabolic process
GO:0009154 purine ribonucleotide catabolic process
GO:0009166 nucleotide catabolic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009214 cyclic nucleotide catabolic process
GO:0009261 ribonucleotide catabolic process
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010035 response to inorganic substance
GO:0010470 regulation of gastrulation
GO:0017038 protein import
GO:0018105 peptidyl-serine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0019439 aromatic compound catabolic process
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030800 negative regulation of cyclic nucleotide metabolic process
GO:0030805 regulation of cyclic nucleotide catabolic process
GO:0030806 negative regulation of cyclic nucleotide catabolic process
GO:0030811 regulation of nucleotide catabolic process
GO:0030812 negative regulation of nucleotide catabolic process
GO:0030814 regulation of cAMP metabolic process
GO:0030815 negative regulation of cAMP metabolic process
GO:0030820 regulation of cAMP catabolic process
GO:0030821 negative regulation of cAMP catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0031348 negative regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0033121 regulation of purine nucleotide catabolic process
GO:0033122 negative regulation of purine nucleotide catabolic process
GO:0033157 regulation of intracellular protein transport
GO:0033673 negative regulation of kinase activity
GO:0034113 heterotypic cell-cell adhesion
GO:0034114 regulation of heterotypic cell-cell adhesion
GO:0034115 negative regulation of heterotypic cell-cell adhesion
GO:0034405 response to fluid shear stress
GO:0034504 protein localization to nucleus
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0034616 response to laminar fluid shear stress
GO:0034655 nucleobase-containing compound catabolic process
GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress
GO:0036473 cell death in response to oxidative stress
GO:0038034 signal transduction in absence of ligand
GO:0042306 regulation of protein import into nucleus
GO:0042308 negative regulation of protein import into nucleus
GO:0042326 negative regulation of phosphorylation
GO:0042542 response to hydrogen peroxide
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042992 negative regulation of transcription factor import into nucleus
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0044270 cellular nitrogen compound catabolic process
GO:0044744 protein targeting to nucleus
GO:0045765 regulation of angiogenesis
GO:0045980 negative regulation of nucleotide metabolic process
GO:0045995 regulation of embryonic development
GO:0046058 cAMP metabolic process
GO:0046434 organophosphate catabolic process
GO:0046700 heterocycle catabolic process
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046823 negative regulation of nucleocytoplasmic transport
GO:0048514 blood vessel morphogenesis
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0051051 negative regulation of transport
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051224 negative regulation of protein transport
GO:0051342 regulation of cyclic-nucleotide phosphodiesterase activity
GO:0051344 negative regulation of cyclic-nucleotide phosphodiesterase activity
GO:0051346 negative regulation of hydrolase activity
GO:0051348 negative regulation of transferase activity
GO:0051531 NFAT protein import into nucleus
GO:0051532 regulation of NFAT protein import into nucleus
GO:0051534 negative regulation of NFAT protein import into nucleus
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0070301 cellular response to hydrogen peroxide
GO:0070375 ERK5 cascade
GO:0070376 regulation of ERK5 cascade
GO:0070377 negative regulation of ERK5 cascade
GO:0070586 cell-cell adhesion involved in gastrulation
GO:0070587 regulation of cell-cell adhesion involved in gastrulation
GO:0071498 cellular response to fluid shear stress
GO:0071499 cellular response to laminar fluid shear stress
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0072523 purine-containing compound catabolic process
GO:0072577 endothelial cell apoptotic process
GO:0090317 negative regulation of intracellular protein transport
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0097193 intrinsic apoptotic signaling pathway
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1900180 regulation of protein localization to nucleus
GO:1900181 negative regulation of protein localization to nucleus
GO:1900407 regulation of cellular response to oxidative stress
GO:1900408 negative regulation of cellular response to oxidative stress
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900543 negative regulation of purine nucleotide metabolic process
GO:1901099 negative regulation of signal transduction in absence of ligand
GO:1901136 carbohydrate derivative catabolic process
GO:1901292 nucleoside phosphate catabolic process
GO:1901342 regulation of vasculature development
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1902175 regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902176 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
GO:1902532 negative regulation of intracellular signal transduction
GO:1902593 single-organism nuclear import
GO:1902882 regulation of response to oxidative stress
GO:1902883 negative regulation of response to oxidative stress
GO:1903201 regulation of oxidative stress-induced cell death
GO:1903202 negative regulation of oxidative stress-induced cell death
GO:1903533 regulation of protein targeting
GO:1903828 negative regulation of cellular protein localization
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:1904589 regulation of protein import
GO:1904590 negative regulation of protein import
GO:1904950 negative regulation of establishment of protein localization
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004707 MAP kinase activity
GO:0005057 receptor signaling protein activity
GO:0051019 mitogen-activated protein kinase binding
Cellular Component GO:0016604 nuclear body
GO:0016605 PML body
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04540 Gap junction
hsa04722 Neurotrophin signaling pathway
hsa04912 GnRH signaling pathway
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-422475: Axon guidance
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-1266738: Developmental Biology
R-HSA-198753: ERK/MAPK targets
R-HSA-202670: ERKs are inactivated
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-450282: MAPK targets/ Nuclear events mediated by MAP kinases
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-198725: Nuclear Events (kinase and transcription factor activation)
R-HSA-8853659: RET signaling
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-166520: Signalling by NGF
R-HSA-198765: Signalling to ERK5
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAPK7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MAPK7 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29483645MelanomaInhibit immunity; immunotherapy targetERK5 is activated by oncogenic BRAF and promotes melanoma growth. Genetic silencing and pharmacological inhibition of ERK5 pathway drastically reduce the growth of melanoma cells and xenografts harboring wild-type (wt) or mutated BRAF (V600E).
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAPK7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAPK7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.060.828
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4730.748
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2430.819
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3940.272
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2370.903
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5980.82
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0130.966
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1420.893
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1620.893
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7050.561
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.170.504
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0880.227
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAPK7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610100-1000.143
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAPK7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAPK7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAPK7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAPK7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAPK7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAPK7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAPK7
Namemitogen-activated protein kinase 7
Aliases BMK1; ERK5; BMK1 kinase; extracellular-signal-regulated kinase 5; PRKM7; BMK-1; ERK-5; MAP kinase 7; MAPK 7; ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAPK7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.